Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

Why is Citi cutting tech jobs in China? How will Trump’s tariffs affect steel prices? What caused Tesla’s China sales to slump? Why did the Fed lift Wells Fargo’s asset cap? How will Amazon’s $10B AI investment impact North Carolina? What led to Shein’s complaint by EU consumer groups? Why is Circle’s IPO pricing above expected range?

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion.
While MoonLake turned down the initial offer, talks may be revived.
The potential deal signals renewed dealmaking activity as investor…

This story appeared on benzinga.com, 2025-06-03 11:38:09.